Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.72 |
| ▸ | CD44 | P16070 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 4/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30199571 | 1.00 | PNMT (0.72) | PNMTCD44MAOBHTR2CADRA2A | |
| Hydrochloric Acid SCHEMBL1124563 | 0.98 | PNMT (0.70) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL11325485 | 0.89 | PNMT (0.62) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL10879871 | 0.86 | PNMT (0.75) | PNMTCD44HTR2CADRA2AADRA2B | |
| SCHEMBL1852509 | 0.84 | PNMT (1.00) | PNMTCD44MAOBHTR2CADRA2A | |
| Ammonia Solution, Strong SCHEMBL20358513 | 0.82 | PNMT (0.96) | PNMTCD44MAOBHTR2CADRA2A | |
| Hydrochloric Acid SCHEMBL1124149 | 0.82 | PNMT (0.96) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL3171440 | 0.81 | PNMT (0.68) | PNMTCD44MAOBHTR2CADRA2A | |
| SCHEMBL31158975 | 0.81 | PNMT (0.68) | PNMTCD44MAOBHTR2CADRA2A | |
| Hydrochloric Acid SCHEMBL1636223 | 0.79 | PNMT (0.66) | PNMTCD44MAOBHTR2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4142874-B1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2026-04-22 | — | — | EP | disclosed |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| EP-4662208-A1 | COMPOUNDS AND COMPOSITIONS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20240327381-A1 | Compounds and Compositions for Selective Degradation of Engineered Proteins | CELGENE CORPORATION (US) | 2024-10-03 | — | — | US | disclosed |
| WO-2024167999-A1 | COMPOUNDS AND COMPOSITIONS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | CELGENE CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2023-05-18 | — | — | US | disclosed |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-4142874-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RaQualia Pharma Inc. (JP) | 2023-03-08 | — | — | EP | disclosed |
| EP-4126847-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO Pharma (FR) | 2023-02-08 | — | — | EP | disclosed |
| US-6831087-B2 | 2-(Pyrid-2- or 4-yl)-1,2,3,4-tetrahydroisoquinoline and derivatives; a good affinity to the NMDA receptor (N-methyl-D-asparate); acute/cronic neurodegenerative diseases; bacterial/viral infections; antidepressants; analgesics | HOFFMANN-LA ROCHE INC. | 2004-12-14 | — | — | US | disclosed |
| US-20040220222-A1 | Malonamide derivatives | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-1448547-A1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20030119870-A1 | Pyridine substituted isoquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | US | disclosed |
| WO-2003040128-A1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-15 | — | — | WO | disclosed |
| EP-0038177-B1 | ANTIALLERGIC IMIDODISULFAMIDES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | SMITHKLINE BECKMAN CORPORATION (US) | 1983-08-31 | — | — | EP | disclosed |
| US-4315935-A | INHIBITING THE SYMPTOMS OF ASTHMA | SMITHKLINE CORPORATION (US) | 1982-02-16 | — | — | US | disclosed |
| EP-0038177-A1 | Antiallergic imidodisulfamides, pharmaceutical compositions containing them and process for their preparation | SMITHKLINE BECKMAN CORPORATION (US) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | NQO2, NQO1, NDUFV2 | PNMT 2451/4885CD44 2225/4885MAOB 902/4885 |
| US-20040220222-A1 | Malonamide derivatives | BACE1, BACE2, APP | PNMT 965/4885CD44 4872/4885MAOB 303/4885 |
| US-20240327381-A1 | Compounds and Compositions for Selective Degradation of Engineered Proteins | TP53, APC, MDM2 | PNMT 3596/4885CD44 411/4885MAOB 3924/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | PNMT 559/4885CD44 4637/4885MAOB 1401/4885 |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | ADRA2C, ADRB2, ADRB3 | PNMT 265/4885CD44 4533/4885MAOB 1536/4885 |
| US-20030119870-A1 | Pyridine substituted isoquinoline derivatives | GRIN1, GRIN2C, GRIN2A | PNMT 457/4885CD44 3948/4885MAOB 1058/4885 |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | PNMT 1811/4885CD44 3065/4885MAOB 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.